ACRIA Studies in Progress

• TH9507 for Lipodystrophy
• UK-427,857 for Drug-Resistant HIV
• Research on Older Adults With HIV: ROAH Program

TH9507 for Lipodystrophy

People who have excess abdominal fat and who are taking anti-HIV drugs will take either TH9507 (an experimental growth hormone releasing factor) or a placebo (dummy pill) for 26 weeks. Participants must be 18-65 years old, with a CD4 count over 100 and a viral load below 1,000.

UK-427,857 for Drug-Resistant HIV

People who have taken anti-HIV drugs from three of the four classes of drugs will take either UK-427 (an experimental HIV CCR5 attachment inhibitor) with an optimized regimen of anti-HIV drugs, or take a placebo (dummy pill) with the optimized regimen, for 11 months. Participants must be 16 or older and have a viral load of at least 5,000.

For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at ext. 124.

Research on Older Adults With HIV: ROAH Program

People in this large study of older adults with HIV will fill out a survey about physical and behavioral health, social networks, quality of life and spirituality. Participants must be 50 or older and be able to read and complete a questionnaire. Study participants will be reimbursed $25 for one visit.

For the ROAH Program, contact Andrew Shippy at 212-924-3934 ext. 104.

ACRIA is forming a Research Community Advisory Board (CAB) to bring the perspective of people with HIV and AIDS into the development and execution of our research projects. To ensure that community values and cultural differences are represented, we want this new CAB to mirror the epidemic as it is today - primarily people of color, increasingly female, and growing older. As a CAB member, you will meet regularly with research staff, review program materials, and help us identify research needs. For more information about this new CAB, please call David Ward at (212) 924-3934, ext. 125.